Tenaya Therapeutics, Inc. (CIK: 0001858848) EDGAR, Information, Filings... CompaniesBIO.Com

Tenaya Therapeutics, Inc.

Mailing address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, Delaware, 94080
Phone
415-865-2066
State location
California
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Filings
N/A

Tenaya Therapeutics, Inc. (CIK: 0001858848) is an American company incorporated in the state of California. Head office is located at 171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, California, 94080. Work in the industry 2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES). Tenaya Therapeutics, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Burroughs Amy L.	0001872564	Dec-05-2022	director
GOEDDEL DAVID V	0001182464	Nov-21-2022	director, 10 percent owner
COLUMN GROUP III-A, LP	0001668085	Nov-21-2022	10 percent owner
COLUMN GROUP III, LP	0001668159	Nov-21-2022	10 percent owner
COLUMN GROUP III GP, LP	0001790965	Nov-21-2022	10 percent owner
Column Group Opportunity III, LP	0001931825	Nov-21-2022	10 percent owner
TCG Opportunity III GP, LLC	0001932445	Nov-21-2022	10 percent owner
Column Group Opportunity III GP, LP	0001932874	Nov-21-2022	10 percent owner
Casdin Capital, LLC	0001534261	Nov-17-2022	director
Casdin Eli	0001534264	Nov-17-2022	director
Parschauer Karah Herdman	0001677455	Dec-22-2021	director
Lee June	0001696493	Nov-19-2021	director
PATTERSON LEONE D	0001233539	Jul-29-2021	officer: Chief Fin and Bus. Officer
Williams R Sanders	0001375347	Jul-29-2021	director
Casdin Partners Master Fund, L.P.	0001534265	Jul-29-2021	10 percent owner
Hoey Timothy	0001553333	Jul-29-2021	officer: Chief Scientific Officer
Walsh Jeffrey T.	0001578251	Jul-29-2021	director
CHEN JIN-LONG	0001642996	Jul-29-2021	director
Ali Faraz	0001667937	Jul-29-2021	director, officer: Chief Executive Officer
Stehman-Breen Catherine	0001702233	Jul-29-2021	director
Casdin Private Growth Equity Fund, L.P.	0001823061	Jul-29-2021	10 percent owner
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC	0001864554	Jul-29-2021	10 percent owner
Tingley Whittemore	0001868494	Jul-29-2021	officer: Chief Medical Officer
Kang JeenJoo	0001868500	Jul-29-2021	director
Srivastava Deepak	0001868501	Jul-29-2021	director

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Tenaya Therapeutics, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001193125-26-249135 ( Act) Size: 0 KB	May-29-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001193125-26-249132 ( Act) Size: 0 KB	May-29-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001193125-26-249131 ( Act) Size: 0 KB	May-29-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001193125-26-249116 ( Act) Size: 0 KB	May-29-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001193125-26-249114 ( Act) Size: 0 KB	May-29-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001193125-26-249113 ( Act) Size: 0 KB	May-29-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001193125-26-249052 ( Act) Size: 0 KB	May-29-2026
8-K	Document	Current report filing Acc-no: 0001193125-26-248680 (34 Act) Size: KB	May-29-2026	001-40656 261045848
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001193125-26-231324 ( Act) Size: 0 KB	May-19-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001193125-26-231323 ( Act) Size: 0 KB	May-19-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001193125-26-231315 ( Act) Size: 0 KB	May-19-2026
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001193125-26-209084 (34 Act) Size: KB	May-06-2026	001-40656 26948874
8-K	Document	Current report filing Acc-no: 0001193125-26-208975 (34 Act) Size: KB	May-06-2026	001-40656 26948503
ARS	Document	Annual report to security holders Acc-no: 0001193125-26-158101 (34 Act) Size: KB	Apr-16-2026	001-40656 26865895
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0001193125-26-158096 (34 Act) Size: KB	Apr-16-2026	001-40656 26865888
DEF 14A	Document	Definitive proxy statements Acc-no: 0001193125-26-158079 (34 Act) Size: KB	Apr-16-2026	001-40656 26865849
10-K	Document	Annual report pursuant to section 13 and 15(d) Acc-no: 0001193125-26-102252 (34 Act) Size: KB	Mar-11-2026	001-40656 26743782
8-K	Document	Current report filing Acc-no: 0001193125-26-102170 (34 Act) Size: KB	Mar-11-2026	001-40656 26743495
8-K	Document	Current report filing Acc-no: 0001193125-26-092654 (34 Act) Size: KB	Mar-05-2026	001-40656 26724300
SCHEDULE 13D/A	Document	Acc-no: 0001193125-26-076892 (34 Act) Size: KB	Feb-26-2026	005-92757 26689300

Recent 20 filings. View all Tenaya Therapeutics, Inc. filings

Overall rating 5.0

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Tenaya Therapeutics, Inc. overview
Tenaya Therapeutics, Inc. job
Tenaya Therapeutics, Inc. stock
Tenaya Therapeutics, Inc. ownership
Tenaya Therapeutics, Inc. CEO
Tenaya Therapeutics, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.